Insulin questions are deceptively simple: you “know” the types… until a vignette forces you to pick the one that matches onset, peak, duration, and real-world use (meals, pumps, DKA, pregnancy, etc.). The trick is that every answer choice is trying to bait a specific misconception—so let’s break one down the way you should on test day.
Tag: Endocrine > Diabetes Mellitus
The Clinical Vignette (USMLE-style)
A 19-year-old man with type 1 diabetes mellitus comes to clinic for follow-up. He recently switched to a basal–bolus regimen. He injects a long-acting insulin once daily and takes a rapid-acting insulin with meals. He reports new episodes of late-afternoon shakiness, sweating, and palpitations that improve after juice. He denies nighttime symptoms. His home glucose log shows hypoglycemia around 4–6 PM.
Which insulin most likely accounts for these late-afternoon hypoglycemic episodes?
A. Insulin aspart
B. Insulin glargine
C. Insulin lispro
D. Insulin NPH
E. Regular insulin
Step 1: Identify the Pattern
Late-afternoon hypoglycemia on a basal–bolus regimen suggests an insulin with a real peak that is “catching” the patient between meals. The classic culprit is NPH, an intermediate-acting insulin with a pronounced peak.
✅ Correct Answer: D. Insulin NPH
Why it fits:
- Intermediate-acting insulin
- Peaks several hours after administration → can cause hypoglycemia between meals and overnight
- Often used as a cheaper “basal-ish” option, sometimes twice daily, but its peak makes it less “flat” than modern basal insulins
High-yield pharmacokinetics (approximate):
- Onset: 1–2 hours
- Peak: 4–12 hours
- Duration: 12–18 hours
Clinical pearl:
If you see hypoglycemia that clusters at predictable times away from meals, think peaks → NPH (or sometimes regular insulin, depending on timing).
The Insulin Cheat Sheet (Know This Cold)
| Insulin | Type | Onset | Peak | Duration | Classic Uses / Notes |
|---|---|---|---|---|---|
| Lispro, Aspart, Glulisine | Rapid-acting | 10–30 min | ~1–3 h | 3–5 h | Meals, correction; pumps; less post-meal hypoglycemia vs regular |
| Regular | Short-acting | 30–60 min | 2–4 h | 5–8 h | IV for DKA, hyperkalemia; must time before meals |
| NPH | Intermediate | 1–2 h | 4–12 h | 12–18 h | Basal alternative; not peakless → hypoglycemia risk |
| Glargine, Detemir | Long-acting | ~1–2 h | No significant peak | ~20–24 h | Basal; lower hypoglycemia risk |
| Degludec | Ultra-long | ~1 h | No peak | > 42 h | Very stable basal; flexible dosing window |
Why Each Distractor Is Wrong (and What It’s Testing)
A. Insulin aspart (Rapid-acting) — Wrong
What they want you to confuse: “Rapid insulin causes hypoglycemia → must be this.”
Why it doesn’t match the vignette:
- Aspart peaks quickly (around meals).
- Late-afternoon hypoglycemia between meals is more consistent with an insulin that peaks hours after dosing, not one used right at lunch and done by late afternoon (unless dosing/timing is clearly mismatched, which the vignette doesn’t emphasize).
High-yield use:
- Take at meals; often used in insulin pumps.
B. Insulin glargine (Long-acting) — Wrong
What they’re testing: Do you know which basal insulins are peakless?
Why it doesn’t match:
- Glargine is designed to be flat with minimal peak.
- It’s chosen specifically to reduce nocturnal and between-meal hypoglycemia compared to NPH.
High-yield fact:
- Glargine precipitates in subcutaneous tissue → slow release (mechanism behind long, steady action).
C. Insulin lispro (Rapid-acting) — Wrong
Same logic as aspart.
Test-day clue:
If symptoms occur predictably hours after injection and away from meals, the question is screaming peak insulin (NPH/regular), not rapid-acting analogs.
E. Regular insulin (Short-acting) — Wrong (for this timing)
What they’re testing: Do you know regular insulin has a later peak than rapid-acting?
Regular insulin can cause between-meal hypoglycemia because it peaks later than rapid-acting insulin. But in a classic basal–bolus regimen, regular insulin is less commonly used for prandial coverage, and the vignette points more strongly to intermediate basal insulin causing predictable afternoon lows.
When regular would be the correct “insulin culprit”:
- Hypoglycemia 2–4 hours after a meal-time dose (because it peaks later)
- Or when the question highlights timing mismatch: patient injects and then delays eating
Ultra high-yield clinical use:
- IV regular insulin is used in:
- DKA (with fluids, potassium management)
- Hyperkalemia (drives K⁺ into cells via Na⁺/K⁺-ATPase)
How to Nail These Questions in 10 Seconds
1) First decide: meal insulin vs basal insulin
- Meal/correction: rapid-acting (lispro/aspart/glulisine) or regular
- Basal: glargine/detemir/degludec (preferred) or NPH (older/cheaper)
2) Then decide: peak vs no peak
- Peakless basal → glargine/detemir/degludec
- Peaky basal → NPH
3) Use timing of hypoglycemia as your “fingerprint”
- Soon after meal: rapid-acting
- 2–4 hours after meal: regular insulin
- Between meals / late afternoon / overnight: NPH (classic), sulfonylureas (if oral agents in stem)
Extra USMLE High-Yield Connections
Insulin adverse effects (common board themes)
- Hypoglycemia (most important)
- Weight gain
- Lipodystrophy at injection sites (rotate sites)
- Hypokalemia (insulin drives K⁺ into cells)
Pregnancy
- Insulin is safe in pregnancy because it does not cross the placenta (it’s a peptide).
- (Clinically, some oral agents are used in practice, but boards love the “insulin is preferred/standard” framing.)
Diabetic emergencies (Step 2 favorites)
- DKA: treat with IV regular insulin, fluids, and careful potassium monitoring
- Start insulin only after assessing K⁺; insulin can worsen hypokalemia.
Rapid Recap
- Late-afternoon hypoglycemia away from meals = think insulin with a peak.
- NPH is intermediate-acting with a significant peak, making it a frequent culprit for between-meal hypoglycemia.
- Rapid-acting analogs (lispro/aspart) are meal-timed and peak early; glargine is designed to be flat; regular insulin is IV in DKA and has a later peak but is less “basal-peaky” than NPH.